<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871778</url>
  </required_header>
  <id_info>
    <org_study_id>PS-G202</org_study_id>
    <secondary_id>2015-004917-26</secondary_id>
    <nct_id>NCT02871778</nct_id>
  </id_info>
  <brief_title>Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia</brief_title>
  <acronym>CLEAN-PCD</acronym>
  <official_title>A Phase 2a, 2-part,Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parion Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and
      the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with
      primary ciliary dyskinesia (PCD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs) in Part A and Part B</measure>
    <time_frame>From the first dose of study drug in each treatment period to the first day of the next treatment period and for 28 days after the last dose in the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in percent predicted FEV1 in Part A and Part B</measure>
    <time_frame>Baseline, after 28 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL), as determined by mean change in QOL-PCD and SGRQ (St. George's Respiratory Questionnaire) scores in Part A and Part B</measure>
    <time_frame>Baseline, after 28 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Primary Ciliary Dyskinesia</condition>
  <arm_group>
    <arm_group_label>VX-371 in Hypertonic Saline (HS), then HS, then HS + Ivacaftor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A/ Treatment Period 1: VX-371 in Hypertonic Saline
Part A/ Treatment Period 2: Hypertonic Saline
Part B/ Treatment Period 3: Hypertonic Saline + Ivacaftor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS, then VX-371 in HS, then VX-371 in HS + Ivacaftor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A/ Treatment Period 1: Hypertonic Saline
Part A/ Treatment Period 2: VX-371 in Hypertonic Saline
Part B/ Treatment Period 3: VX-371 in Hypertonic Saline + Ivacaftor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VX-371, then Placebo, then Placebo + Ivacaftor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A/ Treatment Period 1: VX-371
Part A/ Treatment Period 2: Placebo
Part B/ Treatment Period 3: Placebo + Ivacaftor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then VX-371, then VX-371 + Ivacaftor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A/ Treatment Period 1: Placebo
Part A/ Treatment Period 2: VX-371
Part B/ Treatment Period 3: VX-371 + Ivacaftor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-371</intervention_name>
    <arm_group_label>VX-371 in Hypertonic Saline (HS), then HS, then HS + Ivacaftor</arm_group_label>
    <arm_group_label>HS, then VX-371 in HS, then VX-371 in HS + Ivacaftor</arm_group_label>
    <arm_group_label>VX-371, then Placebo, then Placebo + Ivacaftor</arm_group_label>
    <arm_group_label>Placebo, then VX-371, then VX-371 + Ivacaftor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
    <arm_group_label>VX-371 in Hypertonic Saline (HS), then HS, then HS + Ivacaftor</arm_group_label>
    <arm_group_label>HS, then VX-371 in HS, then VX-371 in HS + Ivacaftor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (0.17% saline)</intervention_name>
    <arm_group_label>VX-371, then Placebo, then Placebo + Ivacaftor</arm_group_label>
    <arm_group_label>Placebo, then VX-371, then VX-371 + Ivacaftor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <arm_group_label>VX-371 in Hypertonic Saline (HS), then HS, then HS + Ivacaftor</arm_group_label>
    <arm_group_label>HS, then VX-371 in HS, then VX-371 in HS + Ivacaftor</arm_group_label>
    <arm_group_label>VX-371, then Placebo, then Placebo + Ivacaftor</arm_group_label>
    <arm_group_label>Placebo, then VX-371, then VX-371 + Ivacaftor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must have evidence supportive of a PCD diagnosis.

          -  Subjects with percent predicted FEV1 of â‰¥40 to &lt;90 percentage points

          -  Non-smoker for at least 90 days prior to the Screening Visit and less than a 5
             pack-year lifetime history of smoking

          -  Stable regimen of medications and chest physiotherapy for the 28 days prior to Day 1

          -  If currently using daily inhaled HS, must be able to discontinue its use for the
             duration of the study.

          -  If taking daily chronic or chronic cycling antibiotics, has been on a consistent
             regimen for at least 4 months prior to the Screening Visit.

          -  Clinically stable (as deemed by the investigator) for at least 14 days prior to the
             Screening Visit

          -  Female subjects of childbearing potential must have a negative serum pregnancy test at
             the Screening Visit. Subjects of childbearing potential and who are sexually active
             must meet the contraception requirements.

        Exclusion Criteria:

          -  Diagnosis of CF based on results of sweat chloride or nasal potential difference (NPD)
             tests or presence of 2 CF-causing mutations in CFTR gene.

          -  History of any organ transplantation or lung resection or chest wall surgery.

          -  Significant congenital heart defects, other than a laterality defect, at the
             discretion of the investigator

          -  Diagnosis of Cri du chat syndrome (chromosome 5p deletion syndrome).

          -  Inability to withhold short-acting bronchodilator use for 4 hours prior to clinic
             visit and long-acting bronchodilator use the night before the first and last clinic
             visit of each treatment period.

          -  Use of diuretics (including amiloride) or renin-angiotensin antihypertensive drugs

          -  Symptoms of acute upper or lower respiratory tract infection, acute pulmonary
             exacerbation, or treatment or was treated with systemic antibiotics for ear or sinus
             disease within 28 days before Day 1 (topical otic antibiotics allowed).

          -  History of significant intolerance to inhaled HS

          -  Pregnant and/or nursing females

          -  Any clinically significant laboratory abnormalities

          -  History of chronic B. cepacia complex or M. abscessus or M. avium

          -  Surgery that required general anesthesia and hospitalization within 3 months of Day 1

        Additional Exclusion Criteria for Part B:

          -  In addition to the exclusion criteria above, subjects who participate in Part B and
             meet any of the following exclusion criteria will not be eligible to continue into
             Part B

          -  Unable to swallow tablets.

          -  Concomitant use of strong or moderate inhibitors or inducers of cytochrome P450 (CYP)
             3A, including consumption of certain herbal medications (e.g., St. John's Wort), and
             grapefruit/grapefruit juice.

          -  Known hypersensitivity to ivacaftor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nina Church</last_name>
    <phone>919-313-1202</phone>
    <email>nchurch@parion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <state>North Rhine-Westphalia</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rabka-Zdroj</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Kartagener Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

